| P2093 | author name string | Masoud Jamei | |
| | Trevor N Johnson | |
| | Karen Rowland-Yeo | |
| P2860 | cites work | Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial | Q24647455 |
| | Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence | Q28257651 |
| | Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. | Q30409445 |
| | Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. | Q30416493 |
| | Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data | Q30666721 |
| | A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data | Q30786488 |
| | Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues | Q31147595 |
| | Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes | Q33373620 |
| | Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model | Q33574126 |
| | Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. | Q33942993 |
| | Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children | Q33998916 |
| | Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events | Q34147623 |
| | Pharmacokinetics of intravenous buprenorphine in children | Q34397617 |
| | Clinical Pharmacokinetics of Digoxin in Infants | Q34686681 |
| | Single-dose pharmacokinetics of ceftriaxone in infants and young children | Q35673633 |
| | Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin | Q36490749 |
| | Methods to evaluate biliary excretion of drugs in humans: an updated review | Q36495774 |
| | Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. | Q36874673 |
| | Birth weight and longitudinal growth in infants born below 32 weeks' gestation: a UK population study | Q37465620 |
| | The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. | Q37521422 |
| | Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review | Q37824590 |
| | Clinical pharmacokinetics of ceftriaxone | Q38730314 |
| | Buprenorphine kinetics | Q39570069 |
| | Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). | Q39779618 |
| | Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice | Q39870288 |
| | Pharmacokinetics of intravenously administered azithromycin in pediatric patients. | Q40452142 |
| | Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling | Q40772216 |
| | Azithromycin clinical pharmacokinetics | Q40804192 |
| | The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin | Q40851439 |
| | Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation | Q42101445 |
| | Pharmacokinetics of Ceftriaxone in Pediatric Patients With Meningitis | Q42177357 |
| | Ceftriaxone pharmacokinetics in newborn infants | Q42275231 |
| | Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding | Q42720364 |
| | The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. | Q43201547 |
| | Pharmacokinetics of ceftriaxione, a third-generation cephalosporin, in pediatric patients. | Q45943207 |
| | Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics | Q46702702 |
| | Clinical pharmacokinetics of mycophenolate mofetil | Q46787320 |
| | mRNA expression of MDR1 and major metabolising enzymes in human fetal tissues | Q48357605 |
| | Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. | Q50951418 |
| | Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. | Q51796989 |
| | Pharmacokinetics of azithromycin in normal and impaired renal function. | Q53009882 |
| P433 | issue | 7 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 1090-1098 | |
| P577 | publication date | 2016-02-09 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach | |
| P478 | volume | 44 | |